Aprogen Turns To IPO To Support Biosimilar Pipeline Expansion
This article was originally published in PharmAsia News
South Korea's Aprogen, which has reached global partnership with Japan's Nichi-Iko for development of its biosimilar versions of Remicade, Herceptin and Rituxan/Mab Thera, is seeking to independently conduct clinical development of other biosimilar products by using the proceeds from its domestic initial public offering.
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.